Guillain-Barre syndrome

(Redirected from Guillian Barre)


Clinical Features

  • Viral illness → ASCENDING, symmetric weakness or paralysis and loss of DTRs
  • Little or no sensory involvement
  • May progress to diaphragm resulting in need for mechanical ventilation (33% of patients)
  • Autonomic dysfunction occurs in 50% of patients


  • Progressive weakness of more than one limb
  • Areflexia


Variants and Subtypes

  • Multiple variants[1][2]
  • Acute inflammatory demyelinating polyneuropathy
    • most common type
    • progressive symmetric muscle weakness
    • often with decreased deep tendon reflexes due to peripheral nerve involvement
  • Acute motor axonal neuropathy
    • often associated with campylobacter infections
    • only motor involvement
  • Acute motor and sensory axonal neuropathy
    • presence both motor and sensory involement
  • Miller-Fisher Syndrome
    • Associated with campylobacter infection
    • More likely to be preceded by diarrhea than viral prodrome
    • Presence of ophthalmoplegia with ataxia and areflexia
    • Weakness is less severe but DESCENDING; disease course milder than classic GBS
    • May present similarly to botulism, which is also descending paralysis

Differential Diagnosis



  • LP
    • Albumin-cytological dissociation of CSF (high protein (>45) and low WBC count (<10)) is most common
    • Patients with HIV can have a pleocytosis[3][4]
  • Typical findings on electromyogram and nerve conduction studies
  • MRI: Selective enhancement of the anterior spinal nerve roots is suggestive[3]



  • Treat non-ambulatory patients within 2 weeks of symptom onset

IVIG vs Plasmapheresis

  • IVIG associated with thromboembolism and aseptic meningitis
  • Plasmapheresis associated with greater hemodynamic instability, lower rate of relapse
  • Combined IVIG and plasmapheresis no better than single therapy (IVIG or plasmapheresis)
  • IVIG preferred due to convenience and availability

Intubation indications

  • Vital capacity <15mL/kg
  • Negative Inspiratory Force < 30 cm H2O
  • PaO2 <70 mm Hg on room air
  • Bulbar dysfunction (difficulty with breathing, swallowing, or speech)
  • Aspiration
  • Avoid succinylcholine during intubation, as this may cause severe hyperkalemia


  • Admit

Indications for admission to ICU

  • Autonomic dysfunction
  • Bulbar dysfunction
  • Initial vital capacity <20 mL/kg
  • Initial negative inspiratory force <–30 cm of water
  • Decrease of >30% of vital capacity or negative inspiratory force
  • Inability to ambulate
  • Treatment with plasmapheresis
  • Anticipated clinical course requiring mechanical ventilation

See Also


  1. Ho TW et al. Guillain-Barrésyndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118 ( Pt 3):597.
  2. Sumner AJ et al. The physiological basis for symptoms in Guillain-Barrésyndrome. Ann Neurol. 1981;9 Suppl:28.
  3. 3.0 3.1 Bunney EB, Gallagher EJ: Peripheral Nerve Disorders, in Marx JA, Hockberger RS, Walls RM, et al (eds): Rosen’s Emergency Medicine: Concepts and Clinical Practice, ed 7. St. Louis, Mosby, Inc., 2010, (Ch) 105:p 1400-1401.
  4. Brannagan TH et al. HIV-associated Guillain-Barré syndrome. J Neurol Sci. 2003;208(1-2):39.